| 彭 敏,翁一鸣,谌 亮.EGFR-TKI联合化疗对比单用EGFR-TKI治疗EGFR突变的晚期非小细胞肺癌疗效与安全性Meta分析[J].中国肿瘤,2018,27(11):874-880. |
| EGFR-TKI联合化疗对比单用EGFR-TKI治疗EGFR突变的晚期非小细胞肺癌疗效与安全性Meta分析 |
| EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone in Non-small Cell Lung Cancer with EGFR Mutations：a Meta-analysis |
| 投稿时间：2018-03-21 |
| DOI：10.11735/j.issn.1004-0242.2018.11.A011 |
|
 |
| 中文关键词: 表皮生长因子受体酪氨酸激酶抑制剂 药物疗法 非小细胞肺癌 Meta分析 |
| 英文关键词:epidermal growth factor receptor-tyrosine kinase inhibitor drug therapy non-small cell lung cancer Meta-analysis |
| 基金项目:国家自然科学基金（81770169；81670123） |
|
| 摘要点击次数: 2112 |
| 全文下载次数: 506 |
| 中文摘要: |
| 摘 要：［目的］ 评价表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitor，EGFR-TKI）联合化疗治疗EGFR突变的晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）患者的疗效与安全性。［方法］ 计算机系统检索PubMed及其他数据库中截止至2017年10月所有使用EGFR-TKI联合化疗对比单用EGFR-TKI治疗EGFR突变晚期NSCLC患者的随机对照试验（randomized controlled trial，RCT）。［结果］ 包含862例患者的5项临床研究符合纳入条件。EGFR-TKI联合化疗可显著延长EGFR突变的晚期NSCLC患者的无进展生存期（progression-free survival，PFS）（HR=0.72，95％CI：0.58~0.91，P=0.006）。两种治疗方式的客观反应率（objective response rate，ORR）（RR=1.06，95％CI：0.94~1.19，P=0.35）及总生存期（overall survival，OS）（HR=1.00，95％CI：0.68~1.47，P=0.99）无差异显著性。两种治疗方法的不良事件（adverse event，AE）发生率较低且相近。［结论］ EGFR-TKI联合化疗在EGFR突变的晚期NSCLC患者中极具应用前景，值得进一步研究。 |
| 英文摘要: |
| Abstract：［Purpose］ To assess the efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI) plus chemotherapy in treating patients having advanced non-small cell lung cancer(NSCLC) with EGFR mutations. ［Methods］ PubMed，Cochrane Library，Embase and ClinicalTrials. gov were searched for randomized controlled trial(RCT) on EGFR-TKI plus chemotherapy in treating advanced NSCLC patients with EGFR mutations up to April，2017. ［Results］ Five RCTs involving 862 patients were eligible. Our meta-analysis demonstrated that EGFR-TKIs plus chemotherapy was significantly better than EGFR-TKI alone in progress free survival (PFS) (HR=0.72，95％CI：0.58～0.91，P=0.006) for advanced NSCLC patients with EGFR mutations. No significant differences were found in either ORR(RR=1.06，95％CI：0.94～1.19，P=0.35) or OS (HR=1.00，95％CI：0.68～1.47，P=0.99). The adverse effect(AE) of both treatments was similarly low. ［Conclusion］ EGFR-TKI plus chemotherapy is a promising treatment for advanced NSCLC patients with EGFR mutations. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |